Staley Capital Advisers Inc Atara Biotherapeutics, Inc. Transaction History

Staley Capital Advisers Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $352,500 - $577,500	250,000 Added 33.33%	1,000,000 $1.48 Million
Q2 2023 Aug 15, 2023	BUY	$1.5 - $3.04 $450,000 - $912,000	300,000 Added 66.67%	750,000 $1.21 Million
Q3 2022 Nov 10, 2022	BUY	$2.85 - $8.73 $71,250 - $218,250	25,000 Added 5.88%	450,000 $1.7 Million
Q2 2022 Aug 05, 2022	BUY	$4.69 - $9.84 $586,250 - $1.23 Million	125,000 Added 41.67%	425,000 $3.31 Million
Q1 2022 May 12, 2022	BUY	$8.44 - $16.89 $422,000 - $844,500	50,000 Added 20.0%	300,000 $2.79 Million
Q1 2021 May 06, 2021	BUY	$14.0 - $20.72 $3.5 Million - $5.18 Million	250,000 New	250,000 $3.59 Million

3.07M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $762M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Staley Capital Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Staley Capital Advisers Inc with notifications on news.